Skip to main content
. 2011 Mar;178(3):1201–1209. doi: 10.1016/j.ajpath.2010.11.073

Figure 4.

Figure 4

Administration of sGal-9 produces potent anti-edema effects. A: sGal-9 was administered intravenously (tail-vein) at three selected doses (10, 30, 60 μg per mouse) 30 minutes before edema induction with CG (right paw) and saline (left paw) in WT mice. PBS (100 μl) was given intravenously as a control. B: sGal-9 (30 μg) or PBS were administered intravenously 24 hours after induction with CG. In all cases, paw volume was assessed by plethysmography and edema calculated as the difference between CG and saline injected paws. Data are expressed as mean ± SEM of six mice per treatment. **P < 0.01, ***P < 0.001 as compared to control (PBS). C–E: Hematoxylin-eosin staining of cellular infiltrate was carried out on paws from the 96-hour time point, respectively, following intravenous administration 24 hours after CG induction with PBS (D) or sGal-9 (30 μg) (E). Control (WT Naïve) was injected with saline alone (C). Images shown are representative of six mice per group with similar results. Scale bar, 200 μm.